Company Overview - Meihua Medical closed at 18.05 yuan, up 1.69%, with a rolling PE ratio of 28.71 times and a total market value of 10.268 billion yuan [1] - The company ranks 65th in the medical device industry, which has an average PE ratio of 51.05 times and a median of 36.62 times [1] - As of the first quarter of 2025, 30 institutions held shares in Meihua Medical, including 24 funds, 4 others, and 2 insurance companies, with a total holding of 42.1394 million shares valued at 1.23 billion yuan [1] Business Operations - Meihua Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices [1] - The main products include home respiratory machine components, artificial cochlear components, other medical product components, precision molds, automation equipment, and home and consumer electronics components [1] - The company is recognized as a national high-tech enterprise and a national intellectual property advantage enterprise, as well as a champion in a specific manufacturing sector in Guangdong Province [1] Financial Performance - In the first quarter of 2025, Meihua Medical achieved an operating income of 296 million yuan, a year-on-year increase of 5.05% [1] - The net profit for the same period was 51.875 million yuan, reflecting a year-on-year decrease of 10.62% [1] - The sales gross margin stood at 39.28% [1]

Investment Rating - The investment rating for the company is "Buy" with a first-time coverage [1] Core Insights - The company has shown stable growth in its two core businesses, with a revenue of 1.594 billion yuan in 2024, representing a year-on-year increase of 19.19%. The net profit attributable to the parent company was 364 million yuan, up 16.11% year-on-year [4][5] - The company is diversifying its business into areas such as blood glucose management and cardiovascular health, indicating the emergence of second and third growth curves [5] - The company has made significant progress in its global industrial layout, with new production facilities in Daya Bay and Malaysia, enhancing its delivery capabilities for overseas business expansion [6] Financial Performance - In Q1 2025, the company achieved a revenue of 296 million yuan, a year-on-year growth of 5.05%, but the net profit decreased by 10.62% to 52 million yuan [4] - The company forecasts revenue growth from 1.942 billion yuan in 2025 to 2.859 billion yuan in 2027, with corresponding net profits expected to rise from 452 million yuan to 668 million yuan during the same period [7][9] - The projected PE ratios for 2025, 2026, and 2027 are 22.2, 18.3, and 15.0 respectively, indicating a favorable valuation trend [7][9]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [4][6]. Core Insights - The company's core business includes the development, manufacturing, and sales of home respiratory devices and cochlear implant components, with expectations for gradual performance improvement in 2025 [2]. - The company has successfully completed the first two phases of its production base in Malaysia, with the third phase expected to be operational by the end of 2025, enhancing its production capacity [3]. - A stock incentive plan has been introduced, reflecting the company's confidence in long-term growth, with performance targets set for 2025-2027 [4]. Summary by Sections Business Performance - The home respiratory device component business is expected to return to normal growth rates in 2024, supported by the Malaysian base potentially mitigating tariff risks [2]. - The revenue from cochlear implant components is showing steady growth, and new product components are experiencing rapid revenue increases [2]. Financial Forecasts - The adjusted net profit forecasts for 2025 and 2026 are 444 million and 539 million yuan, respectively, reflecting a downward revision of 11.6% and 16.0% from previous estimates [4]. - The report projects a net profit of 656 million yuan for 2027, indicating growth potential [4]. Valuation Metrics - The company is positioned as a leader in precision medical device components, with a projected revenue growth rate of 21.13% for 2025 and 20.22% for 2026 [5]. - The estimated P/E ratio for 2025 is 22, with a projected P/B ratio of 2.5, indicating a favorable valuation relative to its growth prospects [5][12].

Company Overview - Meihao Medical closed at 17.25 yuan on June 26, down 1.09%, with a rolling PE ratio of 27.44 times and a total market capitalization of 9.813 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 49.45 times and a median of 35.92 times, placing Meihao Medical at the 63rd position in the industry ranking [1] Shareholding Structure - As of the first quarter of 2025, 30 institutions held shares in Meihao Medical, including 24 funds, 4 others, and 2 insurance companies, with a total shareholding of 42.1394 million shares valued at 1.23 billion yuan [1] Business Operations - Meihao Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices, including home ventilator components, cochlear implant components, and other medical product components [1] - The company is recognized as a national high-tech enterprise and a national intellectual property advantage enterprise, as well as a champion in a specific manufacturing sector in Guangdong Province [1] Financial Performance - In the first quarter of 2025, Meihao Medical reported revenue of 296 million yuan, a year-on-year increase of 5.05%, and a net profit of 51.875 million yuan, reflecting a year-on-year decrease of 10.62%, with a gross profit margin of 39.28% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Meihao Medical, indicating a decline in stock price and a relatively low PE ratio compared to the industry average [1][2] - As of June 18, Meihao Medical's stock closed at 17.04 yuan, down 1.22%, with a rolling PE ratio of 27.11 times and a total market capitalization of 9.694 billion yuan [1] - The average PE ratio for the medical device industry is 49.10 times, with a median of 36.43 times, placing Meihao Medical at the 62nd position within the industry [1][2] Group 2 - In terms of capital flow, on June 18, Meihao Medical experienced a net outflow of 2.0372 million yuan, although it had a total inflow of 8.1495 million yuan over the past five days [1] - The main business of Shenzhen Meihao Chuangyi Medical Technology Co., Ltd. includes the design, development, manufacturing, and sales of precision components and products for medical devices [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 296 million yuan, a year-on-year increase of 5.05%, while net profit was 51.875 million yuan, reflecting a year-on-year decrease of 10.62%, with a gross profit margin of 39.28% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Meihao Medical, which closed at 17.48 yuan with a PE ratio of 27.81 times, significantly lower than the industry average of 50.64 times [1][2] - Meihao Medical's total market capitalization is reported at 99.44 billion yuan, ranking 59th in the medical device industry based on PE ratio [1][2] - The company specializes in the design, development, manufacturing, and sales of precision components and products for medical devices, including home ventilator components and cochlear implant components [1] Group 2 - For the first quarter of 2025, Meihao Medical reported revenue of 296 million yuan, reflecting a year-on-year increase of 5.05%, while net profit decreased by 10.62% to 51.875 million yuan [1] - The gross profit margin for the company stands at 39.28% [1] - As of May 30, 2025, the number of shareholders for Meihao Medical increased to 11,265, with an average holding value of 352,800 yuan per shareholder [1]

证券代码：301363 证券简称：美好医疗 深圳市美好创亿医疗科技股份有限公司 投资者关系活动记录表 | 投资 者 | □特定对象调研 □分析师会议 | | --- | --- | | 关系 活 | □媒体采访业绩说明会 | | 动类别 | □新闻发布会□路演活动 | | | □现场参观 □其他（电话会议） | | 时间 | 2025 年 6 月 6 日（星期五）15:00－17:00 | | 地点 | 深圳证券交易所 8 楼上市大厅 | | 上市 公 | 1、副董事长、副总经理：袁峰 | | 司接 待 | 2、独立董事：王建新 | | 人员 | 3、董事会秘书：谭景霞 | | | 4、副总经理、财务总监：严俊峨 | | | 主要提问及答复情况 | | | 1、副董事长袁峰介绍公司基本情况及海外本土化运营的探索实践 | | | 美好医疗主要从事医疗器械精密组件及产品的设计开发、制造和 | | | 销售，为全球医疗器械企业提供从产品研发到批量交付的全流程一站 | | | 式服务，致力于成为全球卓越的医疗科技服务商。 | | | 公司马来三期产业基地建设项目正在有序推进，以满足客户全球 | | | 供应链对公司 ...

证券代码：301363 证券简称：美好医疗 公告编号：2025-044 深圳市美好创亿医疗科技股份有限公司 关于签订募集资金三方监管协议及补充协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意深圳市美好创亿医疗科技股份有限公 司首次公开发行股票注册的批复》（证监许可〔2022〕1441 号）、深圳证券交易 所《关于深圳市美好创亿医疗科技股份有限公司人民币普通股股票在创业板上市 的通知》（深证上〔2022〕986 号）同意，深圳市美好创亿医疗科技股份有限公 司（以下简称"公司"）首次公开发行人民币普通股（A 股）股票 4,427 万股， 发行价格为 30.66 元/股，募集资金总额 1,357,318,200.00 元，扣除发行费用人民 币 132,529,143.83 元后，募集资金净额为 1,224,789,056.17 元。天健会计师事务 所（特殊普通合伙）已对公司首次公开发行股票的资金到位情况进行了审验，并 于 2022 年 9 月 30 日出具了《验资报告》（天健验〔2022〕3-101 ...

最新一期业绩显示，2025年一季报，公司实现营业收入2.96亿元，同比5.05%；净利润5187.50万元，同 比-10.62%，销售毛利率39.28%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)59美好医疗26.6926.242.7195.46亿行业平均 50.9748.964.68108.42亿行业中值36.6736.602.4749.87亿1天益医疗-1782.30-3052.891.9022.71亿2澳华内 镜-692.58347.365.5572.99亿3诺唯赞-414.64-490.412.2788.73亿4爱朋医疗-382.20290.364.6031.36亿5博晖 创新-331.28525.693.5448.61亿6奥精医疗-149.94-219.761.9827.83亿7硕世生物-138.80-2028.201.2440.60亿 8睿昂基因-101.98-83.721.4513.20亿9康泰医学-86.93-73.453.1057.22亿10中红医疗-72.23-57.610.9150.19亿 11热景生物-59.61-68.684.40131.18亿 来源：金融界 截至202 ...

深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）将于 2025 年 6 月 6 日（星期五）15:00－17:00 参加由深圳证券交易所组织召开的以"乘风远 航・走向广阔新天地"为主题的集体业绩说明会活动，现将有关事项公告如下： 一、本次业绩说明会的安排 1、召开时间：2025 年 6 月 6 日（星期五）15:00－17:00 证券代码：301363 证券简称：美好医疗 公告编号：2025-043 深圳市美好创亿医疗科技股份有限公司 关于参加深圳证券交易所"乘风远航・走向广阔新天地" 2024年度集体业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 二、投资者问题征集方式 为充分尊重投资者、提升交流的针对性，现就本次业绩说明会提前向投资者 公开征集问题，广泛听取投资者的意见和建议。投资者可提前登陆深交所"互动 易"平台（http://irm.cninfo.com.cn）"云访谈"栏目进入本次业绩说明会页面，或 扫描二维码（附后）进入问题征集专题页面进行提问。公司将在本次业绩说明会 上对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参 ...